nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Bexarotene—hematologic cancer	0.0386	0.0829	CbGbCtD
Solifenacin—CYP3A4—Lomustine—hematologic cancer	0.0359	0.0771	CbGbCtD
Solifenacin—CYP3A4—Busulfan—hematologic cancer	0.0359	0.0771	CbGbCtD
Solifenacin—CYP3A4—Thiotepa—hematologic cancer	0.032	0.0687	CbGbCtD
Solifenacin—CYP3A4—Methoxsalen—hematologic cancer	0.0249	0.0534	CbGbCtD
Solifenacin—CYP3A4—Bortezomib—hematologic cancer	0.0237	0.0508	CbGbCtD
Solifenacin—CYP3A4—Daunorubicin—hematologic cancer	0.0226	0.0486	CbGbCtD
Solifenacin—CYP3A4—Cytarabine—hematologic cancer	0.02	0.0429	CbGbCtD
Solifenacin—CYP3A4—Teniposide—hematologic cancer	0.0197	0.0422	CbGbCtD
Solifenacin—CYP3A4—Ifosfamide—hematologic cancer	0.0181	0.039	CbGbCtD
Solifenacin—CYP3A4—Imatinib—hematologic cancer	0.0173	0.0372	CbGbCtD
Solifenacin—CYP3A4—Ruxolitinib—hematologic cancer	0.0163	0.0351	CbGbCtD
Solifenacin—CYP3A4—Nilotinib—hematologic cancer	0.0157	0.0338	CbGbCtD
Solifenacin—CYP3A4—Vinorelbine—hematologic cancer	0.0156	0.0335	CbGbCtD
Solifenacin—CYP3A4—Triamcinolone—hematologic cancer	0.0143	0.0307	CbGbCtD
Solifenacin—CYP3A4—Dasatinib—hematologic cancer	0.0139	0.0299	CbGbCtD
Solifenacin—CYP3A4—Mitoxantrone—hematologic cancer	0.0137	0.0295	CbGbCtD
Solifenacin—CYP3A4—Betamethasone—hematologic cancer	0.0123	0.0263	CbGbCtD
Solifenacin—CYP3A4—Prednisolone—hematologic cancer	0.0121	0.026	CbGbCtD
Solifenacin—CYP3A4—Prednisone—hematologic cancer	0.0114	0.0245	CbGbCtD
Solifenacin—CYP3A4—Irinotecan—hematologic cancer	0.0108	0.0233	CbGbCtD
Solifenacin—CYP3A4—Vinblastine—hematologic cancer	0.00962	0.0207	CbGbCtD
Solifenacin—CYP3A4—Vincristine—hematologic cancer	0.00946	0.0203	CbGbCtD
Solifenacin—CYP3A4—Etoposide—hematologic cancer	0.00867	0.0186	CbGbCtD
Solifenacin—CYP3A4—Dexamethasone—hematologic cancer	0.00713	0.0153	CbGbCtD
Solifenacin—CYP3A4—Doxorubicin—hematologic cancer	0.00591	0.0127	CbGbCtD
Solifenacin—Benazepril—MTHFR—hematologic cancer	0.00116	1	CrCbGaD
Solifenacin—Tachycardia—Betamethasone—hematologic cancer	9.38e-05	0.000216	CcSEcCtD
Solifenacin—Headache—Alitretinoin—hematologic cancer	9.37e-05	0.000215	CcSEcCtD
Solifenacin—Angioedema—Prednisone—hematologic cancer	9.37e-05	0.000215	CcSEcCtD
Solifenacin—Nausea—Thalidomide—hematologic cancer	9.34e-05	0.000215	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—hematologic cancer	9.34e-05	0.000215	CcSEcCtD
Solifenacin—Dyspepsia—Triamcinolone—hematologic cancer	9.32e-05	0.000214	CcSEcCtD
Solifenacin—Rash—Ifosfamide—hematologic cancer	9.32e-05	0.000214	CcSEcCtD
Solifenacin—Dermatitis—Ifosfamide—hematologic cancer	9.31e-05	0.000214	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—hematologic cancer	9.31e-05	0.000214	CcSEcCtD
Solifenacin—Dizziness—Irinotecan—hematologic cancer	9.28e-05	0.000213	CcSEcCtD
Solifenacin—Urticaria—Etoposide—hematologic cancer	9.28e-05	0.000213	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—hematologic cancer	9.23e-05	0.000212	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—hematologic cancer	9.23e-05	0.000212	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—hematologic cancer	9.2e-05	0.000212	CcSEcCtD
Solifenacin—Vomiting—Vincristine—hematologic cancer	9.17e-05	0.000211	CcSEcCtD
Solifenacin—Urticaria—Prednisolone—hematologic cancer	9.15e-05	0.00021	CcSEcCtD
Solifenacin—Asthenia—Cisplatin—hematologic cancer	9.15e-05	0.00021	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—hematologic cancer	9.15e-05	0.00021	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—hematologic cancer	9.14e-05	0.00021	CcSEcCtD
Solifenacin—Fatigue—Triamcinolone—hematologic cancer	9.13e-05	0.00021	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—hematologic cancer	9.1e-05	0.000209	CcSEcCtD
Solifenacin—Rash—Vincristine—hematologic cancer	9.09e-05	0.000209	CcSEcCtD
Solifenacin—Dermatitis—Vincristine—hematologic cancer	9.08e-05	0.000209	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—hematologic cancer	9.08e-05	0.000209	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—hematologic cancer	9.05e-05	0.000208	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—hematologic cancer	9.03e-05	0.000208	CcSEcCtD
Solifenacin—Headache—Vincristine—hematologic cancer	9.03e-05	0.000208	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—hematologic cancer	8.98e-05	0.000206	CcSEcCtD
Solifenacin—Nausea—Carmustine—hematologic cancer	8.97e-05	0.000206	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—hematologic cancer	8.93e-05	0.000205	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—hematologic cancer	8.93e-05	0.000205	CcSEcCtD
Solifenacin—Vomiting—Irinotecan—hematologic cancer	8.93e-05	0.000205	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—hematologic cancer	8.89e-05	0.000204	CcSEcCtD
Solifenacin—Nausea—Alitretinoin—hematologic cancer	8.89e-05	0.000204	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—hematologic cancer	8.87e-05	0.000204	CcSEcCtD
Solifenacin—Hypertension—Prednisone—hematologic cancer	8.85e-05	0.000204	CcSEcCtD
Solifenacin—Rash—Irinotecan—hematologic cancer	8.85e-05	0.000203	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—hematologic cancer	8.85e-05	0.000203	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—hematologic cancer	8.84e-05	0.000203	CcSEcCtD
Solifenacin—Dermatitis—Irinotecan—hematologic cancer	8.84e-05	0.000203	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—hematologic cancer	8.8e-05	0.000202	CcSEcCtD
Solifenacin—Headache—Irinotecan—hematologic cancer	8.8e-05	0.000202	CcSEcCtD
Solifenacin—Nausea—Ifosfamide—hematologic cancer	8.78e-05	0.000202	CcSEcCtD
Solifenacin—Feeling abnormal—Triamcinolone—hematologic cancer	8.73e-05	0.000201	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—hematologic cancer	8.71e-05	0.0002	CcSEcCtD
Solifenacin—Vomiting—Gemcitabine—hematologic cancer	8.7e-05	0.0002	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.67e-05	0.000199	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—hematologic cancer	8.63e-05	0.000198	CcSEcCtD
Solifenacin—Rash—Gemcitabine—hematologic cancer	8.62e-05	0.000198	CcSEcCtD
Solifenacin—Dermatitis—Gemcitabine—hematologic cancer	8.62e-05	0.000198	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—hematologic cancer	8.61e-05	0.000198	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—hematologic cancer	8.6e-05	0.000198	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—hematologic cancer	8.57e-05	0.000197	CcSEcCtD
Solifenacin—Headache—Gemcitabine—hematologic cancer	8.57e-05	0.000197	CcSEcCtD
Solifenacin—Nausea—Vincristine—hematologic cancer	8.56e-05	0.000197	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—hematologic cancer	8.55e-05	0.000197	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisolone—hematologic cancer	8.49e-05	0.000195	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—hematologic cancer	8.46e-05	0.000195	CcSEcCtD
Solifenacin—Dyspepsia—Betamethasone—hematologic cancer	8.46e-05	0.000194	CcSEcCtD
Solifenacin—Dyspepsia—Dexamethasone—hematologic cancer	8.46e-05	0.000194	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—hematologic cancer	8.42e-05	0.000194	CcSEcCtD
Solifenacin—Urticaria—Triamcinolone—hematologic cancer	8.42e-05	0.000193	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—hematologic cancer	8.4e-05	0.000193	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—hematologic cancer	8.39e-05	0.000193	CcSEcCtD
Solifenacin—Asthenia—Etoposide—hematologic cancer	8.38e-05	0.000193	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—hematologic cancer	8.38e-05	0.000193	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisone—hematologic cancer	8.37e-05	0.000192	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—hematologic cancer	8.36e-05	0.000192	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—hematologic cancer	8.36e-05	0.000192	CcSEcCtD
Solifenacin—Decreased appetite—Betamethasone—hematologic cancer	8.36e-05	0.000192	CcSEcCtD
Solifenacin—Decreased appetite—Dexamethasone—hematologic cancer	8.36e-05	0.000192	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—hematologic cancer	8.34e-05	0.000192	CcSEcCtD
Solifenacin—Nausea—Irinotecan—hematologic cancer	8.34e-05	0.000192	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—hematologic cancer	8.32e-05	0.000191	CcSEcCtD
Solifenacin—Infection—Prednisone—hematologic cancer	8.32e-05	0.000191	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—hematologic cancer	8.3e-05	0.000191	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.3e-05	0.000191	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.3e-05	0.000191	CcSEcCtD
Solifenacin—Fatigue—Betamethasone—hematologic cancer	8.29e-05	0.00019	CcSEcCtD
Solifenacin—Fatigue—Dexamethasone—hematologic cancer	8.29e-05	0.00019	CcSEcCtD
Solifenacin—Pruritus—Etoposide—hematologic cancer	8.26e-05	0.00019	CcSEcCtD
Solifenacin—Nervous system disorder—Prednisone—hematologic cancer	8.21e-05	0.000189	CcSEcCtD
Solifenacin—Tachycardia—Prednisone—hematologic cancer	8.17e-05	0.000188	CcSEcCtD
Solifenacin—Skin disorder—Prednisone—hematologic cancer	8.13e-05	0.000187	CcSEcCtD
Solifenacin—Nausea—Gemcitabine—hematologic cancer	8.12e-05	0.000187	CcSEcCtD
Solifenacin—Vomiting—Cisplatin—hematologic cancer	8.11e-05	0.000186	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—hematologic cancer	8.08e-05	0.000186	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—hematologic cancer	8.07e-05	0.000186	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—hematologic cancer	8.06e-05	0.000185	CcSEcCtD
Solifenacin—Rash—Cisplatin—hematologic cancer	8.04e-05	0.000185	CcSEcCtD
Solifenacin—Dermatitis—Cisplatin—hematologic cancer	8.03e-05	0.000185	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—hematologic cancer	8.02e-05	0.000184	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—hematologic cancer	7.97e-05	0.000183	CcSEcCtD
Solifenacin—Feeling abnormal—Betamethasone—hematologic cancer	7.92e-05	0.000182	CcSEcCtD
Solifenacin—Feeling abnormal—Dexamethasone—hematologic cancer	7.92e-05	0.000182	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—hematologic cancer	7.91e-05	0.000182	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.86e-05	0.000181	CcSEcCtD
Solifenacin—Gastrointestinal pain—Betamethasone—hematologic cancer	7.86e-05	0.000181	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—hematologic cancer	7.86e-05	0.000181	CcSEcCtD
Solifenacin—Hypersensitivity—Triamcinolone—hematologic cancer	7.8e-05	0.000179	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—hematologic cancer	7.74e-05	0.000178	CcSEcCtD
Solifenacin—Dizziness—Etoposide—hematologic cancer	7.72e-05	0.000178	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—hematologic cancer	7.7e-05	0.000177	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—hematologic cancer	7.68e-05	0.000177	CcSEcCtD
Solifenacin—Urticaria—Betamethasone—hematologic cancer	7.64e-05	0.000176	CcSEcCtD
Solifenacin—Urticaria—Dexamethasone—hematologic cancer	7.64e-05	0.000176	CcSEcCtD
Solifenacin—Dizziness—Prednisolone—hematologic cancer	7.62e-05	0.000175	CcSEcCtD
Solifenacin—Asthenia—Triamcinolone—hematologic cancer	7.6e-05	0.000175	CcSEcCtD
Solifenacin—Abdominal pain—Dexamethasone—hematologic cancer	7.6e-05	0.000175	CcSEcCtD
Solifenacin—Abdominal pain—Betamethasone—hematologic cancer	7.6e-05	0.000175	CcSEcCtD
Solifenacin—Nausea—Cisplatin—hematologic cancer	7.57e-05	0.000174	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—hematologic cancer	7.56e-05	0.000174	CcSEcCtD
Solifenacin—Pruritus—Triamcinolone—hematologic cancer	7.49e-05	0.000172	CcSEcCtD
Solifenacin—Cough—Methotrexate—hematologic cancer	7.48e-05	0.000172	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—hematologic cancer	7.47e-05	0.000172	CcSEcCtD
Solifenacin—Vomiting—Etoposide—hematologic cancer	7.43e-05	0.000171	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—hematologic cancer	7.42e-05	0.000171	CcSEcCtD
Solifenacin—Dyspepsia—Prednisone—hematologic cancer	7.37e-05	0.000169	CcSEcCtD
Solifenacin—Rash—Etoposide—hematologic cancer	7.36e-05	0.000169	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—hematologic cancer	7.36e-05	0.000169	CcSEcCtD
Solifenacin—Headache—Etoposide—hematologic cancer	7.32e-05	0.000168	CcSEcCtD
Solifenacin—Decreased appetite—Prednisone—hematologic cancer	7.28e-05	0.000167	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—hematologic cancer	7.27e-05	0.000167	CcSEcCtD
Solifenacin—Rash—Prednisolone—hematologic cancer	7.26e-05	0.000167	CcSEcCtD
Solifenacin—Dermatitis—Prednisolone—hematologic cancer	7.26e-05	0.000167	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.25e-05	0.000167	CcSEcCtD
Solifenacin—Fatigue—Prednisone—hematologic cancer	7.22e-05	0.000166	CcSEcCtD
Solifenacin—Headache—Prednisolone—hematologic cancer	7.22e-05	0.000166	CcSEcCtD
Solifenacin—Constipation—Prednisone—hematologic cancer	7.16e-05	0.000165	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—hematologic cancer	7.09e-05	0.000163	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—hematologic cancer	7.05e-05	0.000162	CcSEcCtD
Solifenacin—Dizziness—Triamcinolone—hematologic cancer	7e-05	0.000161	CcSEcCtD
Solifenacin—Cough—Epirubicin—hematologic cancer	7e-05	0.000161	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—hematologic cancer	7e-05	0.000161	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—hematologic cancer	6.99e-05	0.000161	CcSEcCtD
Solifenacin—Infection—Methotrexate—hematologic cancer	6.95e-05	0.00016	CcSEcCtD
Solifenacin—Nausea—Etoposide—hematologic cancer	6.94e-05	0.000159	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—hematologic cancer	6.93e-05	0.000159	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisone—hematologic cancer	6.9e-05	0.000159	CcSEcCtD
Solifenacin—Asthenia—Betamethasone—hematologic cancer	6.9e-05	0.000159	CcSEcCtD
Solifenacin—Asthenia—Dexamethasone—hematologic cancer	6.9e-05	0.000159	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—hematologic cancer	6.86e-05	0.000158	CcSEcCtD
Solifenacin—Gastrointestinal pain—Prednisone—hematologic cancer	6.84e-05	0.000157	CcSEcCtD
Solifenacin—Nausea—Prednisolone—hematologic cancer	6.84e-05	0.000157	CcSEcCtD
Solifenacin—Pruritus—Betamethasone—hematologic cancer	6.8e-05	0.000156	CcSEcCtD
Solifenacin—Pruritus—Dexamethasone—hematologic cancer	6.8e-05	0.000156	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—hematologic cancer	6.79e-05	0.000156	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.78e-05	0.000156	CcSEcCtD
Solifenacin—Vomiting—Triamcinolone—hematologic cancer	6.74e-05	0.000155	CcSEcCtD
Solifenacin—Rash—Triamcinolone—hematologic cancer	6.68e-05	0.000154	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—hematologic cancer	6.68e-05	0.000154	CcSEcCtD
Solifenacin—Dermatitis—Triamcinolone—hematologic cancer	6.67e-05	0.000153	CcSEcCtD
Solifenacin—Urticaria—Prednisone—hematologic cancer	6.65e-05	0.000153	CcSEcCtD
Solifenacin—Headache—Triamcinolone—hematologic cancer	6.64e-05	0.000153	CcSEcCtD
Solifenacin—Abdominal pain—Prednisone—hematologic cancer	6.62e-05	0.000152	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—hematologic cancer	6.6e-05	0.000152	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—hematologic cancer	6.56e-05	0.000151	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—hematologic cancer	6.55e-05	0.00015	CcSEcCtD
Solifenacin—Infection—Epirubicin—hematologic cancer	6.5e-05	0.00015	CcSEcCtD
Solifenacin—Cough—Doxorubicin—hematologic cancer	6.48e-05	0.000149	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—hematologic cancer	6.42e-05	0.000148	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—hematologic cancer	6.41e-05	0.000147	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—hematologic cancer	6.39e-05	0.000147	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—hematologic cancer	6.36e-05	0.000146	CcSEcCtD
Solifenacin—Dizziness—Dexamethasone—hematologic cancer	6.36e-05	0.000146	CcSEcCtD
Solifenacin—Dizziness—Betamethasone—hematologic cancer	6.36e-05	0.000146	CcSEcCtD
Solifenacin—Nausea—Triamcinolone—hematologic cancer	6.29e-05	0.000145	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.28e-05	0.000144	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—hematologic cancer	6.22e-05	0.000143	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—hematologic cancer	6.18e-05	0.000142	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisone—hematologic cancer	6.17e-05	0.000142	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—hematologic cancer	6.16e-05	0.000142	CcSEcCtD
Solifenacin—Vomiting—Betamethasone—hematologic cancer	6.11e-05	0.00014	CcSEcCtD
Solifenacin—Vomiting—Dexamethasone—hematologic cancer	6.11e-05	0.00014	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—hematologic cancer	6.11e-05	0.00014	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—hematologic cancer	6.08e-05	0.00014	CcSEcCtD
Solifenacin—Rash—Betamethasone—hematologic cancer	6.06e-05	0.000139	CcSEcCtD
Solifenacin—Rash—Dexamethasone—hematologic cancer	6.06e-05	0.000139	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—hematologic cancer	6.06e-05	0.000139	CcSEcCtD
Solifenacin—Dermatitis—Betamethasone—hematologic cancer	6.05e-05	0.000139	CcSEcCtD
Solifenacin—Dermatitis—Dexamethasone—hematologic cancer	6.05e-05	0.000139	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.04e-05	0.000139	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—hematologic cancer	6.03e-05	0.000139	CcSEcCtD
Solifenacin—Headache—Betamethasone—hematologic cancer	6.02e-05	0.000138	CcSEcCtD
Solifenacin—Headache—Dexamethasone—hematologic cancer	6.02e-05	0.000138	CcSEcCtD
Solifenacin—Infection—Doxorubicin—hematologic cancer	6.02e-05	0.000138	CcSEcCtD
Solifenacin—Asthenia—Prednisone—hematologic cancer	6.01e-05	0.000138	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—hematologic cancer	5.94e-05	0.000137	CcSEcCtD
Solifenacin—Pruritus—Prednisone—hematologic cancer	5.92e-05	0.000136	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—hematologic cancer	5.91e-05	0.000136	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—hematologic cancer	5.88e-05	0.000135	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—hematologic cancer	5.82e-05	0.000134	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—hematologic cancer	5.76e-05	0.000133	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—hematologic cancer	5.76e-05	0.000132	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—hematologic cancer	5.72e-05	0.000131	CcSEcCtD
Solifenacin—Nausea—Betamethasone—hematologic cancer	5.71e-05	0.000131	CcSEcCtD
Solifenacin—Nausea—Dexamethasone—hematologic cancer	5.71e-05	0.000131	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—hematologic cancer	5.69e-05	0.000131	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.65e-05	0.00013	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—hematologic cancer	5.64e-05	0.00013	CcSEcCtD
Solifenacin—Constipation—Epirubicin—hematologic cancer	5.6e-05	0.000129	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—hematologic cancer	5.56e-05	0.000128	CcSEcCtD
Solifenacin—Dizziness—Prednisone—hematologic cancer	5.54e-05	0.000127	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—hematologic cancer	5.53e-05	0.000127	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—hematologic cancer	5.39e-05	0.000124	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—hematologic cancer	5.38e-05	0.000124	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—hematologic cancer	5.35e-05	0.000123	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—hematologic cancer	5.33e-05	0.000123	CcSEcCtD
Solifenacin—Vomiting—Prednisone—hematologic cancer	5.32e-05	0.000122	CcSEcCtD
Solifenacin—Rash—Prednisone—hematologic cancer	5.28e-05	0.000121	CcSEcCtD
Solifenacin—Dermatitis—Prednisone—hematologic cancer	5.27e-05	0.000121	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—hematologic cancer	5.27e-05	0.000121	CcSEcCtD
Solifenacin—Headache—Prednisone—hematologic cancer	5.24e-05	0.000121	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.23e-05	0.00012	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—hematologic cancer	5.22e-05	0.00012	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—hematologic cancer	5.2e-05	0.00012	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—hematologic cancer	5.18e-05	0.000119	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—hematologic cancer	5.18e-05	0.000119	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—hematologic cancer	5.15e-05	0.000118	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—hematologic cancer	5.02e-05	0.000115	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—hematologic cancer	4.99e-05	0.000115	CcSEcCtD
Solifenacin—Nausea—Prednisone—hematologic cancer	4.97e-05	0.000114	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.95e-05	0.000114	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—hematologic cancer	4.95e-05	0.000114	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—hematologic cancer	4.82e-05	0.000111	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—hematologic cancer	4.81e-05	0.000111	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—hematologic cancer	4.79e-05	0.00011	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—hematologic cancer	4.7e-05	0.000108	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—hematologic cancer	4.63e-05	0.000106	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—hematologic cancer	4.63e-05	0.000106	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—hematologic cancer	4.46e-05	0.000103	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—hematologic cancer	4.45e-05	0.000102	CcSEcCtD
Solifenacin—Rash—Methotrexate—hematologic cancer	4.41e-05	0.000101	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—hematologic cancer	4.41e-05	0.000101	CcSEcCtD
Solifenacin—Headache—Methotrexate—hematologic cancer	4.38e-05	0.000101	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—hematologic cancer	4.35e-05	9.99e-05	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—hematologic cancer	4.33e-05	9.95e-05	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—hematologic cancer	4.29e-05	9.85e-05	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—hematologic cancer	4.16e-05	9.57e-05	CcSEcCtD
Solifenacin—Nausea—Methotrexate—hematologic cancer	4.16e-05	9.55e-05	CcSEcCtD
Solifenacin—Rash—Epirubicin—hematologic cancer	4.13e-05	9.49e-05	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—hematologic cancer	4.12e-05	9.48e-05	CcSEcCtD
Solifenacin—Headache—Epirubicin—hematologic cancer	4.1e-05	9.43e-05	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—hematologic cancer	4.01e-05	9.21e-05	CcSEcCtD
Solifenacin—Nausea—Epirubicin—hematologic cancer	3.89e-05	8.94e-05	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—hematologic cancer	3.85e-05	8.85e-05	CcSEcCtD
Solifenacin—Rash—Doxorubicin—hematologic cancer	3.82e-05	8.78e-05	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—hematologic cancer	3.82e-05	8.77e-05	CcSEcCtD
Solifenacin—Headache—Doxorubicin—hematologic cancer	3.79e-05	8.72e-05	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—hematologic cancer	3.6e-05	8.27e-05	CcSEcCtD
Solifenacin—CHRM4—Signaling by GPCR—HRAS—hematologic cancer	9.05e-06	9.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	8.99e-06	9.15e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	8.97e-06	9.13e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	8.97e-06	9.12e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1B—hematologic cancer	8.89e-06	9.05e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADCY7—hematologic cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA3—hematologic cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	8.88e-06	9.04e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ESR1—hematologic cancer	8.82e-06	8.98e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NUP214—hematologic cancer	8.82e-06	8.98e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—hematologic cancer	8.8e-06	8.95e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ESR1—hematologic cancer	8.8e-06	8.95e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CD—hematologic cancer	8.74e-06	8.9e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CASP3—hematologic cancer	8.72e-06	8.87e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FN1—hematologic cancer	8.72e-06	8.87e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ESR1—hematologic cancer	8.71e-06	8.86e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL2—hematologic cancer	8.7e-06	8.86e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FN1—hematologic cancer	8.69e-06	8.84e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—HRAS—hematologic cancer	8.67e-06	8.82e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—hematologic cancer	8.66e-06	8.81e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCG2—hematologic cancer	8.64e-06	8.79e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTR—hematologic cancer	8.64e-06	8.79e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—hematologic cancer	8.63e-06	8.78e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	8.61e-06	8.76e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BAD—hematologic cancer	8.61e-06	8.76e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FN1—hematologic cancer	8.6e-06	8.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BAD—hematologic cancer	8.58e-06	8.74e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	8.58e-06	8.74e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	8.53e-06	8.68e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	8.52e-06	8.67e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	8.5e-06	8.65e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BAD—hematologic cancer	8.5e-06	8.65e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	8.5e-06	8.65e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCND1—hematologic cancer	8.49e-06	8.64e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ENO2—hematologic cancer	8.47e-06	8.62e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—JUN—hematologic cancer	8.47e-06	8.62e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	8.43e-06	8.58e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	8.42e-06	8.57e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CD80—hematologic cancer	8.36e-06	8.5e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—hematologic cancer	8.35e-06	8.5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KIT—hematologic cancer	8.34e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	8.34e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	8.34e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2—hematologic cancer	8.34e-06	8.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CD80—hematologic cancer	8.33e-06	8.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	8.31e-06	8.46e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KIT—hematologic cancer	8.31e-06	8.46e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	8.31e-06	8.46e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—hematologic cancer	8.29e-06	8.44e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3R1—hematologic cancer	8.25e-06	8.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CD80—hematologic cancer	8.25e-06	8.39e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KIT—hematologic cancer	8.23e-06	8.38e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	8.23e-06	8.38e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	8.23e-06	8.38e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTT1—hematologic cancer	8.22e-06	8.36e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	8.21e-06	8.35e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	8.19e-06	8.34e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTEN—hematologic cancer	8.19e-06	8.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	8.17e-06	8.31e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCND1—hematologic cancer	8.13e-06	8.27e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—JUN—hematologic cancer	8.11e-06	8.25e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	8.09e-06	8.23e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SDC1—hematologic cancer	8.03e-06	8.17e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	8.01e-06	8.15e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	7.99e-06	8.13e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	7.99e-06	8.13e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	7.96e-06	8.1e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CREB1—hematologic cancer	7.94e-06	8.08e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CREB1—hematologic cancer	7.91e-06	8.05e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	7.89e-06	8.02e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	7.86e-06	8e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTEN—hematologic cancer	7.84e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BRAF—hematologic cancer	7.84e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CREB1—hematologic cancer	7.84e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BRAF—hematologic cancer	7.81e-06	7.95e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EP300—hematologic cancer	7.81e-06	7.95e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL2—hematologic cancer	7.77e-06	7.91e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6R—hematologic cancer	7.74e-06	7.88e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL2—hematologic cancer	7.74e-06	7.88e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BRAF—hematologic cancer	7.74e-06	7.88e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	7.73e-06	7.87e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6R—hematologic cancer	7.72e-06	7.86e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	7.71e-06	7.84e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	7.67e-06	7.81e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL2—hematologic cancer	7.67e-06	7.8e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	7.65e-06	7.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6R—hematologic cancer	7.65e-06	7.78e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	7.63e-06	7.77e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CB—hematologic cancer	7.62e-06	7.75e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—hematologic cancer	7.6e-06	7.73e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EP300—hematologic cancer	7.48e-06	7.61e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	7.4e-06	7.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	7.38e-06	7.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	7.36e-06	7.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	7.33e-06	7.46e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—hematologic cancer	7.32e-06	7.45e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	7.31e-06	7.44e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NRAS—hematologic cancer	7.31e-06	7.44e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	7.29e-06	7.41e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—hematologic cancer	7.27e-06	7.4e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.26e-06	7.39e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	7.24e-06	7.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	7.24e-06	7.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	7.18e-06	7.31e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.17e-06	7.3e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	7.16e-06	7.28e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	7.09e-06	7.21e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	7.08e-06	7.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGF2—hematologic cancer	7.02e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—hematologic cancer	7.01e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	7e-06	7.12e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGF2—hematologic cancer	7e-06	7.12e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NRAS—hematologic cancer	7e-06	7.12e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGF2—hematologic cancer	6.93e-06	7.05e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	6.92e-06	7.05e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	6.9e-06	7.02e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	6.83e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CD44—hematologic cancer	6.83e-06	6.95e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NQO1—hematologic cancer	6.83e-06	6.95e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—hematologic cancer	6.81e-06	6.93e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	6.79e-06	6.91e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JAK2—hematologic cancer	6.73e-06	6.85e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JAK2—hematologic cancer	6.71e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	6.7e-06	6.82e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JAK2—hematologic cancer	6.64e-06	6.76e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	6.6e-06	6.71e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTEN—hematologic cancer	6.58e-06	6.7e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	6.57e-06	6.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MDM2—hematologic cancer	6.57e-06	6.69e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MDM2—hematologic cancer	6.55e-06	6.66e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—hematologic cancer	6.52e-06	6.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	6.51e-06	6.63e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	6.5e-06	6.62e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MDM2—hematologic cancer	6.48e-06	6.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYCS—hematologic cancer	6.46e-06	6.58e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.42e-06	6.54e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MTOR—hematologic cancer	6.39e-06	6.5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	6.39e-06	6.5e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MTOR—hematologic cancer	6.37e-06	6.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	6.37e-06	6.48e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	6.31e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MTOR—hematologic cancer	6.31e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KRAS—hematologic cancer	6.29e-06	6.4e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—EP300—hematologic cancer	6.28e-06	6.39e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	6.1e-06	6.21e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	6.08e-06	6.19e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	6.02e-06	6.13e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KRAS—hematologic cancer	6.02e-06	6.13e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	6e-06	6.1e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	5.98e-06	6.08e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	5.93e-06	6.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	5.92e-06	6.03e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	5.91e-06	6.02e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—hematologic cancer	5.88e-06	5.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2—hematologic cancer	5.87e-06	5.97e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—hematologic cancer	5.86e-06	5.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	5.86e-06	5.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2—hematologic cancer	5.85e-06	5.95e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—hematologic cancer	5.84e-06	5.94e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—hematologic cancer	5.82e-06	5.92e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—hematologic cancer	5.8e-06	5.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2—hematologic cancer	5.79e-06	5.9e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	5.78e-06	5.88e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—hematologic cancer	5.76e-06	5.87e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCND1—hematologic cancer	5.72e-06	5.82e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JUN—hematologic cancer	5.71e-06	5.81e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCND1—hematologic cancer	5.7e-06	5.8e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.7e-06	5.8e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JUN—hematologic cancer	5.69e-06	5.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCND1—hematologic cancer	5.65e-06	5.75e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JUN—hematologic cancer	5.64e-06	5.74e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—hematologic cancer	5.59e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	5.54e-06	5.63e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	5.53e-06	5.63e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTEN—hematologic cancer	5.52e-06	5.62e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	5.52e-06	5.62e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTEN—hematologic cancer	5.5e-06	5.6e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	5.46e-06	5.56e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTEN—hematologic cancer	5.45e-06	5.55e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	5.4e-06	5.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.39e-06	5.49e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	5.39e-06	5.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	5.39e-06	5.48e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	5.37e-06	5.47e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—hematologic cancer	5.35e-06	5.45e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—HRAS—hematologic cancer	5.35e-06	5.44e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	5.33e-06	5.43e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	5.32e-06	5.41e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EP300—hematologic cancer	5.27e-06	5.36e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EP300—hematologic cancer	5.25e-06	5.34e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.23e-06	5.33e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.23e-06	5.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EP300—hematologic cancer	5.2e-06	5.29e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—hematologic cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—HRAS—hematologic cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—hematologic cancer	5.12e-06	5.21e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—hematologic cancer	5.11e-06	5.2e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—hematologic cancer	5.06e-06	5.15e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	4.99e-06	5.08e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	4.97e-06	5.06e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—hematologic cancer	4.94e-06	5.03e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NRAS—hematologic cancer	4.93e-06	5.01e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	4.92e-06	5.01e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—hematologic cancer	4.92e-06	5.01e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NRAS—hematologic cancer	4.91e-06	5e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—hematologic cancer	4.9e-06	4.99e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—hematologic cancer	4.88e-06	4.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NRAS—hematologic cancer	4.86e-06	4.95e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—hematologic cancer	4.72e-06	4.8e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	4.72e-06	4.8e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	4.7e-06	4.79e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	4.66e-06	4.74e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—hematologic cancer	4.64e-06	4.73e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.63e-06	4.71e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—hematologic cancer	4.59e-06	4.67e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	4.58e-06	4.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—hematologic cancer	4.57e-06	4.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	4.56e-06	4.64e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—hematologic cancer	4.53e-06	4.61e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—hematologic cancer	4.52e-06	4.6e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	4.52e-06	4.6e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KRAS—hematologic cancer	4.24e-06	4.32e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KRAS—hematologic cancer	4.23e-06	4.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KRAS—hematologic cancer	4.19e-06	4.26e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	3.9e-06	3.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.89e-06	3.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	3.88e-06	3.95e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	3.85e-06	3.91e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—hematologic cancer	3.79e-06	3.86e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—hematologic cancer	3.77e-06	3.84e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—hematologic cancer	3.76e-06	3.82e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—hematologic cancer	3.72e-06	3.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HRAS—hematologic cancer	3.6e-06	3.67e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.6e-06	3.67e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HRAS—hematologic cancer	3.59e-06	3.66e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HRAS—hematologic cancer	3.56e-06	3.62e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—hematologic cancer	3.45e-06	3.51e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—hematologic cancer	3.44e-06	3.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.42e-06	3.48e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—hematologic cancer	3.41e-06	3.47e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—hematologic cancer	3.37e-06	3.43e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.23e-06	3.28e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—hematologic cancer	3.18e-06	3.24e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—hematologic cancer	3.17e-06	3.23e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—hematologic cancer	3.14e-06	3.2e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.98e-06	3.03e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTEN—hematologic cancer	2.57e-06	2.62e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—EP300—hematologic cancer	2.45e-06	2.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.82e-06	1.85e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—hematologic cancer	1.48e-06	1.51e-05	CbGpPWpGaD
